Vasilisa A. Polozkova, Eleonora R. Pereverzeva, Sofiya G. Yazeryan, Ivan A. Efremov, Andrey E. Shchekotikhin

Evaluation of cardiotoxicity of a new antitumor compound, anthrafuran, a derivative of anthracycline antibiotics

Introduction

Evaluation of cardiotoxicity of a new antitumor compound, anthrafuran, a derivative of anthracycline antibiotics. Discover Anthrafuran (AF), a new antitumor compound showing no cardiotoxicity in rats. Unlike Doxorubicin, AF's safety profile suggests high potential for clinical development.

Abstract

Introduction: Anthracyclines and anthracenedione derivatives are a group of anticancer drugs that are widely used in clinical practice. Their application is frequently limited by cardiotoxic effects. The aim of this study was to evaluate the cardiotoxicity of the new anthracenedione derivative Anthrafuran (AF) in comparison with Doxorubicin (Dox) and Mitoxantrone (MT). Materials and Methods: The study was conducted on 50 adult female Wistar rats. AF, MT, and Dox were administered in therapeutic doses and regimens for this animal species (AF: 20 mg/kg x 3/48 per os; MT: 1 mg/kg x 3/96 i.v.; Dox: 2.5 mg/kg x 3/72 i.v.). Electrocardiographic (ECG) parameters and heart weight index were determined; histological evaluation of the myocardium was performed on days 1 and 30 post-treatment. Results: Dox intravenous injections in therapeutic doses caused a pronounced cardiotoxic effect. The signs of cardiac decompensation manifested as a significant decrease in heart rate (HR) (Dox 486±6, control 522±12.8), prolongation of the QT interval (Dox 0.06±0.002, control 0.048±0.001), an increase in weight index of the heart (Dox 0.41±0.03, control 0.36±0.006), and myocardial damage. Although the cardiotoxicity of MT was less pronounced, it nevertheless negatively affected both ECG parameters (HR 465±15, QT 0.056±0.002) and the structure of the heart muscle. The use of AF did not cause any pathological changes and had no effect on the heart weight index or ECG parameters (HR 498±7.3, QT 0.052±0.003, weight index of the heart 0.35±0.009). Conclusion: Unlike Dox (2.5 mg/kg x 3/72 i.v.) and MT (1 mg/kg x 3/96 i.v.), the new anthracenedione derivative AF (20 mg/kg x 3/48 per os) in therapeutic doses does not possess cardiotoxic properties, supporting its potential for clinical study.

Review

This abstract presents a timely and highly relevant study evaluating the cardiotoxicity of Anthrafuran (AF), a novel anthracenedione derivative, in comparison to the well-established cardiotoxic agents Doxorubicin (Dox) and Mitoxantrone (MT). The central finding that AF, at therapeutic doses, does not induce pathological changes in cardiac parameters or histology, unlike Dox and MT, is of significant interest to the field of oncology. The use of a multi-faceted approach, including ECG parameters, heart weight index, and histological analysis, provides a robust preliminary assessment of cardiac health, strengthening the reported conclusions regarding AF's non-cardiotoxic profile. While the study's design of comparing AF to Dox and MT is appropriate, some methodological details warrant further consideration in the full manuscript. A key point for discussion is the differing routes of administration: AF was given *per os*, while Dox and MT were administered intravenously. Although therapeutic equivalence is stated, a thorough justification of how these differing routes and associated bioavailability affect the comparability of cardiotoxicity between the compounds would be beneficial. Additionally, while assessments at days 1 and 30 post-treatment offer valuable initial insights, anthracycline-induced cardiotoxicity can manifest chronically; thus, longer-term follow-up could provide a more complete picture of AF's safety profile. The abstract provides numerical data, but explicit statistical comparisons (e.g., p-values) would further solidify the claims of "pronounced" versus "less pronounced" cardiotoxicity. Despite these considerations, the abstract clearly demonstrates the potential of Anthrafuran as a promising new anticancer drug candidate with a significantly improved cardiotoxicity profile compared to its predecessors. This finding has substantial implications for clinical practice, potentially reducing one of the most debilitating side effects of cancer chemotherapy. Future research should ideally focus on elucidating the precise mechanisms underlying AF's lack of cardiotoxicity, exploring its efficacy as an antitumor agent, and conducting further chronic toxicity studies to fully support its advancement towards preclinical and, ultimately, clinical development. Overall, the study offers compelling preliminary data that underscore Anthrafuran's potential to address a critical unmet need in oncology.

Full Text

Comments

You need to be logged in to post a comment.